Who is this course for?
People seeking an overview of investigational psilocybin therapy, including those interested in mental health research and treatment development.
An overview of investigational psilocybin therapy and how it is being studied for mental health conditions. It explains the treatment process, including preparation, the dosing session, and integration.
COMPASS Pathways
English
8 hours
This page explains investigational psilocybin therapy, also described as psilocybin treatment, and how it is being studied with psychological support for certain mental health conditions. It notes that COMPASS Pathways has developed an investigational synthesised formulation of psilocybin called COMP360. The content covers what happens during psilocybin therapy, including preparation, the dosing session, and integration afterward. It describes the session environment, the role of the therapist, and the use of music and an eye mask during the experience. The page is primarily informational and also outlines COMPASS Pathways’ clinical development programme and the conditions being researched, including treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa.
People seeking an overview of investigational psilocybin therapy, including those interested in mental health research and treatment development.
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
People seeking an overview of investigational psilocybin therapy, including those interested in mental health research and treatment development.
Format: Self-paced. Time commitment: 8 hours.
The listed price is Price on request. Confirm the latest tuition, fees, and payment options with [object Object].
The listing includes a certificate signal. Accreditation note: CME. Confirm credential eligibility directly with the provider before enrolling.
The listed next cohort date is 2026-06-01.
The current listing status is Discontinued. Use the provider website for the latest enrollment status.
By Therapsil
Shares course skills
A 106-hour live online training in psilocybin-assisted psychotherapy with an Aotearoa New Zealand-specific curriculum, delivered in partnership with PsyTrain. It is designed to support clinical practice with supervised learning and expert faculty input.
Next cohort: Jun 1, 2026
Source lists: 106 hours
Delivery: Online
No medicine self-experience listed
By Fluence
Shares course skills
This page lists courses on ketamine use in therapy and ketamine-assisted treatment for mental health conditions. The listings include training on safety, screening, administration, integration, and related clinical topics, with some courses noting continuing education eligibility and in-person or experiential component
Next cohort: Jul 13, 2026
By Therapsil
Shares course skills
Fundamentals of MDMA-Assisted Psychotherapy is a training course on safely and effectively guiding clients through therapeutic MDMA experiences. It includes live seminars, experiential retreats, and integration practice in in-person or online formats.
Next cohort: Aug 2, 2026
Source lists: 122 hours
Delivery: Online + Vancouver, Canada + Canada
Includes medicine self-experience